FDA accepts Krystal Biotech's biologics license application for genetic skin disorder DEB

Aug. 18, 2022 5:26 PM ETKrystal Biotech, Inc. (KRYS)By: Anuron Mitra, SA News Editor
  • Krystal Biotech (NASDAQ:KRYS) on Thursday said the U.S. FDA had accepted its biologics license application for its gene therapy B-VEC for the treatment of dystrophic epidermolysis bullosa (DEB).
  • DEB  is a genetic skin disorder affecting skin and nails that usually presents at birth.
  • The FDA said it would decide upon the application by Feb. 17, 2023, or the so-called Prescription Drug User Fee Act date.
  • The FDA granted the application a priority review designation.
  • The agency said it is not currently planning to hold an advisory committee meeting to discuss the application.
  • KRYS stock -1.7% to $73.14 in postmarket trading.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.